Sanofi, Doudna-founded Scribe Therapeutics to target sickle cell disease in new pact
Sanofi has inked another collaboration with its CRISPR partner Scribe Therapeutics as the duo seeks to create a newer, safer approach to tackling sickle cell disease.
The French pharma giant will pay Scribe $40 million upfront, and it could dish out more than $1.2 billion down the road for milestones across an undisclosed number of programs that will combine Scribe’s so-called CRISPR X-editing tech and Sanofi’s non-viral delivery technologies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.